Conference Proceedings
Updates from ICARIA-MM, a Phase 3 Study of Isatuximab (Isa) Plus Pomalidomide and Low-Dose Dexamethasone (Pd) vs Pd in Relapsed and Refractory Multiple Myeloma (RRMM)
Paul G Richardson, Aurore Perrot, Jesus San-Miguel, Meral Beksac, Ivan Spicka, Xavier Leleu, Fredrik Schjesvold, Philippe Moreau, Meletios A Dimopoulos, Jeffrey Shang-Yi Huang, Jiri Minarik, Michele Cavo, H Miles Prince, Cheng Zheng, Franck Dubin, Helgi van de Velde, Kenneth C Anderson
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | CIG MEDIA GROUP, LP | Published : 2021
Abstract
Background Isa is an approved monoclonal antibody that binds to a specific epitope on the CD38 receptor. Phase 3 ICARIA-MM study (NCT02990338) demonstrated improved progression-free survival (PFS) with Isa-Pd vs Pd (P=0.001) and manageable safety profile. Here, we report updated ICARIA results. Methods Patients with RRMM (N=307) who received ≥2 prior therapies, including lenalidomide (Len) and a proteasome inhibitor (PI), were randomized to Isa-Pd (n=154) or Pd (n=153). Isa was administered intravenously at 10 mg/kg weekly for 4 weeks and every other week thereafter. This pre-planned second interim analysis assessed time to next treatment (TTNT), overall survival (OS), time from randomizatio..
View full abstract